AN2 Therapeutics, Inc.

ANTX Nasdaq SEC CIK 1880438
Follow AN2 Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$8M +14.9% vs same quarter last year
EPS, diluted −$0.17 +45.2% vs same quarter last year
Operating cash flow −$6.1M +4.3% vs same quarter last year
Operating income −$8.7M +13.6% vs same quarter last year
Net income by quarter
−$7.5M
−$10.6M
−$6.5M
−$9.4M
−$8.7M
−$10M
−$8.2M
−$8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$80M−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$35.2M
FY24−$51.3M
FY23−$64.7M
FY22−$41M
FY21−$21.5M
FY20-